AUTHORS
Kaitlyn Ziegele, B.S., Judie Zeni2, Bernard Lawrence Marini Jr, PharmD, BCOP, FHOPA3, Anthony John Perissinotti, PharmD, BCOP4, Julia Brown, PharmD5, Madeleine King, PharmD, BCOP6, Irene Ryan, PA-C7, Dale Lee Bixby, MD, PhD8, Patrick W. Burke, MD9, Lydia L Benitez, PharmD, BCOP10
AFFILIATIONS
1 University of Michigan College of Pharmacy, Ann Arbor, Michigan, United States
2 University of Michigan College of Pharmacy, Ann Arbor, Michigan, United States
3 University of Michigan College of Pharmacy, Ann Arbor, Michigan, United States
4 University of Michigan Health, Ann Arbor, Michigan, United States
5 University of Michigan Health, Ann Arbor, Michigan, United States
6 University of Michigan Health, Ann Arbor, Michigan, United States
7 University of Michigan Health, Ann Arbor, Michigan, United States
8 University of Michigan Health, Ann Arbor, Michigan, United States
9 University of Michigan Health, Ann Arbor, Michigan, United States
10 University of Michigan College of Pharmacy, Ann Arbor, Michigan, United States
ABSTRACT
Background:
Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) that receive pediatric or pediatric-inspired chemotherapy regimens with high-dose corticosteroids are at increased risk for osteonecrosis (ON). A comparison of outcomes between children and AYAs receiving Children’s Oncology Group T-cell ALL protocols reported higher incidence of ON in AYAs (17% vs. 4.8%; Colace et al. Blood, 2023). Nonetheless, there are limited reports of the total incidence and characteristics of ON in AYAs including functional impact or implications on quality of life, and factors associated with toxicity. We characterized the incidence and clinical consequences of ON and explored associated risk factors for ON.
Methods:
This single center retrospective review included AYA patients (15-39 yrs) with ALL receiving pediatric or pediatric-inspired regimens in the frontline setting from Jan 2014-June 2024. Patients were excluded if they had a prior diagnosis of ON or had a history of chronic steroid use prior to treatment. Patients were followed from induction until ON event or last-follow-up and censored at the time of proceeding to alternative treatment for relapse or hematopoietic transplant (HCT). Patient characteristics, treatments received, and outcomes of interest were extracted from the electronic medical record. ON was confirmed by reviewing clinical progress notes and capturing imaging modality for diagnosis. Severity was graded using CTCAE criteria version 6.0. Incidence of ON was analyzed by cohorts based on induction steroid utilized, and subsequently a case-control analysis was performed to identify factors associated with development of ON. The primary endpoint was the incidence of all-grade ON. Secondary endpoints included the incidence of high-grade ON, association of induction steroid on the incidence of ON, and factors associated with ON. Descriptive statistics were performed on clinical variables of interest. Cohort comparisons were performed via Fisher’s exact test or a Mann-Whitney U test. A multivariate logistic regression model was conducted to evaluate risk factors for ON including the impact of age.
Results:
A total of 83 patients were included with a median age of 23.5 years (range 15- 40 years), 56 (68%) males, and 74 (89%) non-Hispanic. 53 (64%) patients had B-cell ALL and 30 (36%) patients had T-cell ALL. Induction chemotherapy regimens included the following: Michigan-modified CALGB10403 (n= 41, 49%), COG AALL 1131 (n= 18, 22%), CALGB 10403 (n=10, 12%), COG AALL 1231 (n=6, 7%), COG AALL 0434 (n=2, 2%), and other BFM (n=6, 7%). Dexamethasone was utilized during induction in 17 (20%) patients while 66 (80%) patients received prednisone.
All-grade ON occurred in 23 (28%) patients, 41% of patients who received dexamethasone and 24% of those who received prednisone during induction (p=0.224). Grade III or higher ON occurred in 11 (13%) patients. The median time to ON occurrence in those with an event 24 months (range 2-86 months). Impact on daily activities was documented for 9 (39% of ON events) cases and required surgical intervention in 9 (39% of ON events) cases. Hips and knees were the most common sites, reported in 11 (48%) and 9 (39%) cases, respectively. The median dexamethasone cumulative exposure was 3.3 mg/kg for patients diagnosed with ON and 1.0 mg/kg for patients without ON (p=0.010), and the median pre-maintenance steroid exposure (in prednisone equivalents) was 43.7 mg/kg for patients diagnosed with ON and 33.6 mg/kg for patients without (p=0.075). Factors associated with increased risk of ON in a multivariable analysis were higher cumulative dexamethasone exposure (OR = 1.34, 95% CI [1.02-1.75], p=0.037) and age 30 years or older (OR = 3.37, 95% CI [1.04-10.9], p=0.043).
Conclusion:
Osteonecrosis was common and frequently clinically consequential among AYAs receiving pediatric or pediatric-inspired ALL therapy. Older age and greater cumulative dexamethasone exposure were associated with ON.
DISCLOSURES
Lydia L Benitez, PharmD, BCOP: No relevant conflicts of interest to declare.